Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 4/20 | 0.47 |
| ▸ | FNTB | P49356 | 4/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4959069 | 0.87 | FNTA (0.43) | FNTAFNTBPGGT1BLTA4H | |
| SCHEMBL2213322 | 0.85 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL2213310 | 0.85 | FNTA (0.49) | FNTAFNTBPGGT1B | |
| SCHEMBL3382819 | 0.84 | ALPI (0.42) | FNTAFNTBPGGT1B | |
| Formic Acid SCHEMBL27865482 | 0.82 | FNTA (0.52) | FNTAFNTBPGGT1BLTA4HMME | |
| SCHEMBL907360 | 0.81 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4HMME | |
| SCHEMBL907359 | 0.81 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4HMME | |
| SCHEMBL16430977 | 0.81 | LTA4H (0.58) | FNTAFNTBPGGT1BLTA4HMME | |
| SCHEMBL16430978 | 0.81 | LTA4H (0.58) | FNTAFNTBPGGT1BLTA4HMME | |
| SCHEMBL3646826 | 0.81 | FNTA (0.56) | FNTAFNTBPGGT1BLTA4HMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140166-A2 | NOVEL ADJUVANT FOR SUBUNIT OR COMPONENT VACCINES | VIROGENETICS CORPORATION (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000035482-A2 | NOVEL ADJUVANT FOR SUBUNIT OR COMPONENT VACCINES | VIROGENETICS CORPORATION (US) | 2000-06-22 | — | — | WO | claimed |
| US-5750354-A | Lipoxin transport system and uses therefor | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1998-05-12 | — | — | US | claimed |
| EP-3669894-A2 | NOVEL MULTIFUNCTIONAL COMPOUNDS FOR PHARMACEUTICAL PURPOSES | Syntab Therapeutics GmbH (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-10202421-B2 | Tumor-targeting compounds | SYNTAB THERAPEUTICS GMBH (DE) | 2019-02-12 | — | — | US | disclosed |
| US-20170096452-A1 | Novel Tumor-Targeting Compounds | SYNTAB THERAPEUTICS GMBH (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20160367620-A1 | GLUTATHIONE | DEMOPOULOS HARRY B (US) | 2016-12-22 | — | — | US | disclosed |
| US-8470963-B2 | Multifunctional compounds for pharmaceutical purposes | SKU ASSET MANAGEMENT GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8209131-B2 | Inflammation, allergic diseases, metastatic cancers, pathogen infections; glycosaminoglycan related molecules | CURTIN UNIVERSITY OF TECHNOLOGY (AU) | 2012-06-26 | — | — | US | disclosed |
| US-20120010153-A1 | NOVEL TUMOR-TARGETING COMPOUNDS | SKU ASSET MANAGEMENT GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| EP-2387421-A1 | COMPOUNDS COMPRISING N-FORMYL-METHIONINE RESIDUES AND TUMOR-TARGETING PEPTIDES | SKU Asset Management GmbH (DE) | 2011-11-23 | — | — | EP | disclosed |
| EP-1743649-A1 | Treatment and diagnosis of infertility using TGF beta or activin | The University of Adelaide (AU) | 2007-01-17 | — | — | EP | disclosed |
| US-20070010451-A1 | Method of protecting cells against damage and pharmaceutical composition comprising leumorphin | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2007-01-11 | — | — | US | disclosed |
| EP-0755406-B1 | METHOD AND PRODUCT FOR REGULATING CELL RESPONSIVENESS TO EXTERNAL SIGNALS | NAT JEWISH CT IMMUN & RESPIRAT (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6872536-B1 | Chemotactic peptide antagonists for imaging sites of inflammation | BRACCO IMAGING S.P.A. (IT) | 2005-03-29 | — | — | US | disclosed |
| US-20020094549-A1 | Screening methods for presqualene diphosphate analogs | SERHAN CHARLES N (US) | 2002-07-18 | — | — | US | disclosed |
| US-6395874-B1 | A PROTEIN; THERAPY FOR STROKES, ARTHRITIS, PULMONARY ADULT RESPIRATORY DISTRESS SYNDROME, ATHEROSCLEROSIS AND INFLAMMATION OF THE EYE | DOHENY EYE INSTITUTE | 2002-05-28 | — | — | US | disclosed |
| EP-1140166-A2 | NOVEL ADJUVANT FOR SUBUNIT OR COMPONENT VACCINES | VIROGENETICS CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035482-A2 | NOVEL ADJUVANT FOR SUBUNIT OR COMPONENT VACCINES | VIROGENETICS CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
| US-4803197-A | ANTIINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202421-B2 | Tumor-targeting compounds | TP53, MYC, KRAS | FNTA 190/4885FNTB 138/4885PGGT1B 478/4885 |
| US-20120010153-A1 | NOVEL TUMOR-TARGETING COMPOUNDS | TP53, TPX2, KRAS | FNTA 480/4885FNTB 246/4885PGGT1B 498/4885 |
| US-20170096452-A1 | Novel Tumor-Targeting Compounds | TP53, TPX2, KRAS | FNTA 480/4885FNTB 246/4885PGGT1B 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.